Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
MIAMI, May 5, 2025 ~ Immorta Bio Inc, a scientific longevity company, has announced that it will be presenting a talk at the upcoming Clinical Immunology Symposium of the American Association of Immunologists Annual Meeting. The talk, titled "Immunologically Mediated Senolysis", will take place on Monday, May 5 at 8:15 AM in Room 316C at the Haw 'ai Convention Center.
The company, which is dedicated to "Treating Diseases of Aging and Treating Aging as Disease", will be joined by presentations from Pfizer and the University of Pittsburgh. Immorta Bio is known for being the first company to develop a "senolytic immunotherapy" for the treatment of cancer and aging. This innovative treatment involves training the immune system to selectively kill "senescent cells" that contribute to aging and also act as a barrier against immune responses. By removing this defense mechanism, cancer becomes vulnerable to attack by the immune system.
More on The PennZone
According to Immorta Bio, their lead senolytic immunotherapy product, SenoVax™, has shown promising results in animal models for various types of cancer such as lung, breast, pancreatic, brain cancers and melanoma. Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio expressed his excitement about being chosen to present their work on using the immune system to fight cancer and aging alongside other esteemed panelists.
The company's research on how SenoVax™ enables its anticancer effects through T cell mediated mechanisms has been previously published in peer-reviewed literature with collaborations from University of California San Diego, Georgetown University, Ceders Sainai, and Calidi Bio. Additionally, Immorta Bio recently demonstrated that natural killer cell activation resulting from SenoVax™ therapy also plays a role in stimulating cancer destruction.
Dr. Boris Reznik, President and CEO of Immorta Bio stated that their company is founded on the principle of "Scientific Longevity" and being chosen to give an oral presentation at such a prestigious and exclusive scientific gathering as AAI2025 is a validation of their science. The company is dedicated to advancing the field of longevity and finding innovative ways to treat diseases associated with aging.
The company, which is dedicated to "Treating Diseases of Aging and Treating Aging as Disease", will be joined by presentations from Pfizer and the University of Pittsburgh. Immorta Bio is known for being the first company to develop a "senolytic immunotherapy" for the treatment of cancer and aging. This innovative treatment involves training the immune system to selectively kill "senescent cells" that contribute to aging and also act as a barrier against immune responses. By removing this defense mechanism, cancer becomes vulnerable to attack by the immune system.
More on The PennZone
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
According to Immorta Bio, their lead senolytic immunotherapy product, SenoVax™, has shown promising results in animal models for various types of cancer such as lung, breast, pancreatic, brain cancers and melanoma. Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio expressed his excitement about being chosen to present their work on using the immune system to fight cancer and aging alongside other esteemed panelists.
The company's research on how SenoVax™ enables its anticancer effects through T cell mediated mechanisms has been previously published in peer-reviewed literature with collaborations from University of California San Diego, Georgetown University, Ceders Sainai, and Calidi Bio. Additionally, Immorta Bio recently demonstrated that natural killer cell activation resulting from SenoVax™ therapy also plays a role in stimulating cancer destruction.
Dr. Boris Reznik, President and CEO of Immorta Bio stated that their company is founded on the principle of "Scientific Longevity" and being chosen to give an oral presentation at such a prestigious and exclusive scientific gathering as AAI2025 is a validation of their science. The company is dedicated to advancing the field of longevity and finding innovative ways to treat diseases associated with aging.
Filed Under: Business
0 Comments
Latest on The PennZone
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- Nurse leader Julie Nyhus has been named editorial director of American Nurse Journal
- ABM for Good™ Launches First Project with Build Change
- Braces for Teenagers in Allentown Offered by Exeter Smiles
- Roots for Boots to Host "Bike Day Bash" Featuring Trike Presentation to Local Veteran
- JOSHWAY Cuts Ribbon on New Brick-and-Mortar Location
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
- GormanSquared Announces Provisional Patent
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027